Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC

Hedge fund increases stake in biotech company by nearly 85%

Mar. 16, 2026 at 11:07am

Got story updates? Submit your updates here. ›

HighVista Strategies LLC, a hedge fund, increased its position in Nuvalent, Inc. (NASDAQ:NUVL) by 84.9% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 93,294 shares of the company's stock, making it one of Nuvalent's largest institutional investors.

Why it matters

This increase in HighVista's stake in Nuvalent suggests the hedge fund sees significant potential in the biotech company's pipeline of targeted cancer therapies. As one of Nuvalent's largest shareholders, HighVista's investment could signal growing investor confidence in the company's drug development efforts.

The details

According to the 13F filing, HighVista Strategies acquired an additional 42,834 shares of Nuvalent during the third quarter, bringing its total position to 93,294 shares. This represents approximately 0.13% of Nuvalent's outstanding shares and makes HighVista one of the company's top 10 institutional investors.

  • HighVista Strategies increased its Nuvalent holdings during the third quarter of 2026.

The players

HighVista Strategies LLC

A hedge fund that has increased its stake in Nuvalent, Inc. to become one of the company's largest institutional investors.

Nuvalent, Inc.

A clinical-stage precision oncology company focused on developing targeted therapies for patients with genetically defined cancers.

Got photos? Submit your photos here. ›

The takeaway

HighVista Strategies' increased investment in Nuvalent suggests growing institutional confidence in the biotech company's ability to advance its pipeline of innovative cancer treatments. As one of Nuvalent's largest shareholders, HighVista's stake could signal a positive outlook for the company's future prospects.